In today’s recent session, 3.52 million shares of the TG Therapeutics Inc (NASDAQ:TGTX) have been traded, and its beta is 2.21. Most recently the company’s share price was $20.33, and it changed around $3.12 or 18.11% from the last close, which brings the market valuation of the company to $3.14B. TGTX at last check was trading at a discount to its 52-week high of $23.12, offering almost -13.72% off that amount. The share price’s 52-week low was $6.46, which indicates that the recent value has risen by an impressive 68.22% since then. We note from TG Therapeutics Inc’s average daily trading volume that its 10-day average is 2.57 million shares, with the 3-month average coming to 2.64 million.
TG Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.56. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended TGTX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Instantly TGTX has been showing a green trend so far today with a performance of 18.11% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 20.35 on recent trading dayincreased the stock’s daily price by 0.1%. The company’s shares are currently up 19.01% year-to-date, but still up 5.82% over the last five days. On the other hand, TG Therapeutics Inc (NASDAQ:TGTX) is 3.98% up in the 30-day period. We can see from the shorts that 32.18 million shares have been sold at a short interest cover period of 11.59 day(s).
The consensus price target as assigned by Wall Street analysts is $23, which translates to bulls needing to increase their stock price by 11.61% from its current value. Analyst projections state that TGTX is forecast to be at a low of $5 and a high of $49.
TG Therapeutics Inc (TGTX) estimates and forecasts
TG Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 32.77 percent over the past six months and at a -111.11% annual growth rate that is well below the industry average of 13.70%.
TGTX Dividends
TG Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Aug-06.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.55% of TG Therapeutics Inc shares, and 59.87% of them are in the hands of institutional investors. The stock currently has a share float of 66.20%. TG Therapeutics Inc stock is held by 323.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-03-31, it held 9.4602% of the shares, which is about 13.54 million shares worth $205.9 million.
BLACKROCK INC., with 7.578% or 10.84 million shares worth $164.93 million as of 2024-03-31, holds the second largest percentage of outstanding shares.
